{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T06:32:27Z","timestamp":1792737147091,"version":"4.5.0"},"reference-count":28,"publisher":"American Medical Association (AMA)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"\n Importance<\/jats:title>\n Thyroid storm is the most severe form of thyrotoxicosis, with high mortality, and is treated with propylthiouracil and methimazole. Some guidelines recommend propylthiouracil over methimazole, although the difference in outcomes associated with each treatment is unclear.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To compare outcomes associated with use of propylthiouracil vs methimazole for the treatment of thyroid storm.<\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n \n This comparative effectiveness study comprised a large, multicenter, US-based cohort from the Premier Healthcare Database between January 1, 2016, and December 31, 2020. It included 1383 adult patients admitted to intensive or intermediate care units with a diagnosis of thyroid storm per\n International Statistical Classification of Diseases and Related Health Problems, Tenth Revision<\/jats:italic>\n codes and treated with either propylthiouracil or methimazole. Analyses were conducted from July 2022 to February 2023.\n <\/jats:p>\n <\/jats:sec>\n \n Exposure<\/jats:title>\n Patients received either propylthiouracil or methimazole for treatment of thyroid storm. Exposure was assigned based on the initial thionamide administered.<\/jats:p>\n <\/jats:sec>\n \n Main Outcomes and Measures<\/jats:title>\n The primary outcome was the adjusted risk difference of in-hospital death or discharge to hospice between patients treated with propylthiouracil and those treated with methimazole, assessed by targeted maximum likelihood estimation.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n A total of 1383 patients (656 [47.4%] treated with propylthiouracil; mean [SD] age, 45 [16] years; 473 women [72.1%]; and 727 [52.6%] treated with methimazole; mean [SD] age, 45 [16] years; 520 women [71.5%]) were included in the study. The standardized mean difference for age was 0.056, and the standardized mean difference for sex was 0.013. The primary composite outcome occurred in 7.4% of of patients (102 of 1383; 95% CI, 6.0%-8.8%). A total of 8.5% (56 of 656; 95% CI, 6.4%-10.7%) of patients who initiated propylthiouracil and 6.3% (46 of 727; 95% CI, 4.6%-8.1%) who initiated methimazole died in the hospital (adjusted risk difference, 0.6% [95% CI, \u22121.8% to 3.0%];\n P<\/jats:italic>\n \u2009=\u2009.64). There were no significant differences in duration of organ support, total hospitalization costs, or rates of adverse events between the 2 treatment groups.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusion and Relevance<\/jats:title>\n In this comparative effectiveness study of a multicenter cohort of adult patients with thyroid storm, no significant differences were found in mortality or adverse events in patients who were treated with propylthiouracil or methimazole. Thus, current guidelines recommending propylthiouracil over methimazole for treatment of thyroid storm may merit reevaluation.<\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2023.8655","type":"journal-article","created":{"date-parts":[[2023,4,17]],"date-time":"2023-04-17T11:02:22Z","timestamp":1681729342000},"page":"e238655","source":"Crossref","is-referenced-by-count":41,"title":["Comparison of Propylthiouracil vs Methimazole for Thyroid Storm in Critically Ill Patients"],"prefix":"10.1001","volume":"6","author":[{"given":"Sun Y.","family":"Lee","sequence":"first","affiliation":[{"name":"Department of Medicine, Section of Endocrinology, Diabetes, Nutrition & Weight Management, Boston University Chobanian & Avedisian School of Medicine, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine L.","family":"Modzelewski","sequence":"additional","affiliation":[{"name":"Department of Medicine, Section of Endocrinology, Diabetes, Nutrition & Weight Management, Boston University Chobanian & Avedisian School of Medicine, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anica C.","family":"Law","sequence":"additional","affiliation":[{"name":"Department of Medicine, The Pulmonary Center, Boston University Chobanian & Avedisian School of Medicine, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allan J.","family":"Walkey","sequence":"additional","affiliation":[{"name":"Department of Medicine, The Pulmonary Center, Boston University Chobanian & Avedisian School of Medicine, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth N.","family":"Pearce","sequence":"additional","affiliation":[{"name":"Department of Medicine, Section of Endocrinology, Diabetes, Nutrition & Weight Management, Boston University Chobanian & Avedisian School of Medicine, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas A.","family":"Bosch","sequence":"additional","affiliation":[{"name":"Department of Medicine, The Pulmonary Center, Boston University Chobanian & Avedisian School of Medicine, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2023,4,17]]},"reference":[{"issue":"10047","key":"zoi230275r1","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1016\/S0140-6736(16)00278-6","article-title":"Hyperthyroidism.","volume":"388","author":"De Leo","year":"2016","journal-title":"Lancet"},{"issue":"1","key":"zoi230275r2","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1172\/JCI107744","article-title":"Triiodothyronine and thyroxine in hyperthyroidism: comparison of the acute changes during therapy with antithyroid agents.","volume":"54","author":"Abuid","year":"1974","journal-title":"J Clin Invest"},{"issue":"10","key":"zoi230275r3","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1089\/thy.2016.0229","article-title":"2016 American Thyroid Association guidelines for diagnosis and management of hyperthyroidism and other causes of thyrotoxicosis.","volume":"26","author":"Ross","year":"2016","journal-title":"Thyroid"},{"key":"zoi230275r4","doi-asserted-by":"publisher","DOI":"10.1507\/endocrj.EJ16-0336","author":"Satoh","year":"2016","journal-title":"Endocr J"},{"issue":"6","key":"zoi230275r5","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1111\/cen.2016.84.issue-6","article-title":"Treatment and management of thyroid storm: analysis of the nationwide surveys: the taskforce committee of the Japan Thyroid Association and Japan Endocrine Society for the establishment of diagnostic criteria and nationwide surveys for thyroid storm.","volume":"84","author":"Isozaki","year":"2016","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"4","key":"zoi230275r7","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1016\/j.jclinepi.2007.11.008","article-title":"The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies.","volume":"61","author":"von Elm","year":"2008","journal-title":"J Clin Epidemiol"},{"issue":"8","key":"zoi230275r8","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1111\/j.1524-4733.2009.00600.x","article-title":"Good research practices for comparative effectiveness research: defining, reporting and interpreting nonrandomized studies of treatment effects using secondary data sources: the ISPOR Good Research Practices for Retrospective Database Analysis Task Force Report\u2014Part I.","volume":"12","author":"Berger","year":"2009","journal-title":"Value Health"},{"issue":"13","key":"zoi230275r9","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1001\/jama.2022.2910","article-title":"Effect of antiplatelet therapy on survival and organ support\u2013free days in critically ill patients with COVID-19: a randomized clinical trial.","volume":"327","author":"Bradbury","year":"2022","journal-title":"JAMA"},{"issue":"6","key":"zoi230275r10","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1513\/AnnalsATS.202111-1251RL","article-title":"Predictive validity of the Sequential Organ Failure Assessment Score versus claims-based scores among critically ill patients.","volume":"19","author":"Bosch","year":"2022","journal-title":"Ann Am Thorac Soc"},{"issue":"7","key":"zoi230275r11","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1097\/00003246-200107000-00002","article-title":"Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care.","volume":"29","author":"Angus","year":"2001","journal-title":"Crit Care Med"},{"issue":"4","key":"zoi230275r14","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1056\/NEJMoa041895","article-title":"Perioperative beta-blocker therapy and mortality after major noncardiac surgery.","volume":"353","author":"Lindenauer","year":"2005","journal-title":"N Engl J Med"},{"key":"zoi230275r15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18637\/jss.v051.i13","article-title":"tmle: an R package for targeted maximum likelihood estimation.","volume":"51","author":"Gruber","year":"2012","journal-title":"J Stat Softw"},{"issue":"1","key":"zoi230275r16","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1093\/aje\/kww165","article-title":"Targeted maximum likelihood estimation for causal inference in observational studies.","volume":"185","author":"Schuler","year":"2017","journal-title":"Am J Epidemiol"},{"issue":"2","key":"zoi230275r18","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1037\/0012-1649.44.2.395","article-title":"Using full matching to estimate causal effects in nonexperimental studies: examining the relationship between adolescent marijuana use and adult outcomes.","volume":"44","author":"Stuart","year":"2008","journal-title":"Dev Psychol"},{"issue":"7","key":"zoi230275r20","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000002848","article-title":"Factors associated with mortality of thyroid storm: analysis using a national inpatient database in Japan.","volume":"95","author":"Ono","year":"2016","journal-title":"Medicine (Baltimore)"},{"issue":"3","key":"zoi230275r21","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1007\/s11739-020-02445-6","article-title":"Epidemiology and factors associated with mortality of thyroid storm in Taiwan: a nationwide population-based study.","volume":"16","author":"Kornelius","year":"2021","journal-title":"Intern Emerg Med"},{"issue":"11","key":"zoi230275r22","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.1089\/thy.2022.0096","article-title":"Estimating incidence and case fatality of thyroid storm in Germany between 2007 and 2017: a claims data analysis.","volume":"32","author":"Thiyagarajan","year":"2022","journal-title":"Thyroid"},{"issue":"1","key":"zoi230275r23","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1089\/thy.2018.0275","article-title":"National trends in incidence, mortality, and clinical outcomes of patients hospitalized for thyrotoxicosis with and without thyroid storm in the United States, 2004-2013.","volume":"29","author":"Galindo","year":"2019","journal-title":"Thyroid"},{"issue":"7","key":"zoi230275r24","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1164\/rccm.201801-0118PP","article-title":"Clinical knowledge from observational studies: everything you wanted to know but were afraid to ask.","volume":"198","author":"Gershon","year":"2018","journal-title":"Am J Respir Crit Care Med"},{"issue":"2","key":"zoi230275r25","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/S0889-8529(18)30165-8","article-title":"Life-threatening thyrotoxicosis: thyroid storm.","volume":"22","author":"Burch","year":"1993","journal-title":"Endocrinol Metab Clin North Am"},{"issue":"7","key":"zoi230275r26","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1089\/thy.2011.0334","article-title":"Diagnostic criteria, clinical features, and incidence of thyroid storm based on nationwide surveys.","volume":"22","author":"Akamizu","year":"2012","journal-title":"Thyroid"},{"issue":"1","key":"zoi230275r27","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1186\/s12913-020-05207-4","article-title":"Comprehensive review of ICD-9 code accuracies to measure multimorbidity in administrative data.","volume":"20","author":"Wei","year":"2020","journal-title":"BMC Health Serv Res"},{"issue":"5","key":"zoi230275r28","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1097\/MED.0b013e3283565b49","article-title":"The propylthiouracil dilemma.","volume":"19","author":"Glinoer","year":"2012","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"key":"zoi230275r19","volume-title":"Statistical Power Analysis for the Behavioral Sciences","author":"Cohen","year":"1988","edition":"2nd ed"},{"key":"zoi230275r6","unstructured":"Bosch? N. Comparative effectiveness of propylthiouracil versus methimazole among critically ill patients with thyroid storm: a target trial emulation. Published online July 21, 2022. Accessed September 8, 2022. https:\/\/osf.io\/c72z9\/?view_only=717fcaf5dbb3484fbc1807b69cc9f644"},{"key":"zoi230275r12","unstructured":"Elixhauser? A, Friedman? B, Stranges? E. Septicemia in U.S. Hospitals, 2009: Statistical Brief #122. Healthcare Cost and Utilization Project (HCUP) Statistical Briefs. Agency for Healthcare Research and Quality. 2011. Accessed February 23, 2021. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK65391\/"},{"key":"zoi230275r13","unstructured":"Gasparini? A, Salmasian H, Williman J, Chia SY, Teo E. Comorbidity: computing comorbidity scores. Published online January 17, 2022. Accessed March 10, 2022. https:\/\/CRAN.R-project.org\/package=comorbidity"},{"key":"zoi230275r17","unstructured":"van der Laan? MJ, Rubin? D. Targeted maximum likelihood learning. October 2006. U.C. Berkeley Division of Biostatistics Working Paper Series. Working Paper 213. Accessed March 15, 2023. https:\/\/biostats.bepress.com\/ucbbiostat\/paper213"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2803923\/lee_2023_oi_230275_1680890810.84907.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,17]],"date-time":"2023-04-17T11:02:29Z","timestamp":1681729349000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2803923"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,17]]},"references-count":28,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,4,3]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2023.8655","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.742613791.793599876","asserted-by":"object"}]},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,17]]}}}